Ceredex Value Advisors LLC Has $50.33 Million Position in Danaher Corporation $DHR

Key Points

• Ceredex Value Advisors LLC increased its stake in Danaher Corporation by 10.1%, acquiring an additional 22,442 shares, bringing its total ownership to 245,515 shares valued at approximately $50.3 million.
• Danaher stock recently faced a decline of 1.8% and has a current average target price of $247.61 based on evaluations from 17 investment analysts with a "Buy" rating.
• During the recent quarter, Danaher reported earnings of $1.80 EPS, exceeding expectations, with revenue of $5.94 billion, a 3.4% increase from the same quarter last year.

Ceredex Value Advisors LLC boosted its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 10.1% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 245,515 shares of the conglomerate's stock after acquiring an additional 22,442 shares during the period. Danaher comprises about 1.1% of Ceredex Value Advisors LLC's investment portfolio, making the stock its 27th biggest holding. Ceredex Value Advisors LLC's holdings in Danaher were worth $50,331,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in shares of Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock valued at $12,296,123,000 after purchasing an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Danaher by 3.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock valued at $4,016,404,000 after acquiring an additional 612,154 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after acquiring an additional 194,466 shares during the period. Northern Trust Corp increased its stake in shares of Danaher by 14.3% during the fourth quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock valued at $1,821,477,000 after acquiring an additional 992,594 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Danaher by 11.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock valued at $1,303,163,000 after acquiring an additional 579,046 shares during the period. Institutional investors own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. UBS Group lowered their price objective on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research note on Wednesday, July 23rd. Evercore ISI decreased their price target on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Guggenheim restated a "buy" rating and issued a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Finally, Robert W. Baird lifted their price target on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research report on Friday, July 18th. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $247.61.

Insider Buying and Selling

In related news, Director Teri List sold 2,778 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 11.10% of the company's stock.

Danaher Trading Up 0.4%

Danaher stock traded up $0.80 during midday trading on Friday, reaching $206.09. The stock had a trading volume of 1,979,809 shares, compared to its average volume of 3,319,294. The firm's fifty day simple moving average is $201.65 and its two-hundred day simple moving average is $199.49. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The firm has a market cap of $147.57 billion, a price-to-earnings ratio of 43.85, a PEG ratio of 2.87 and a beta of 0.73.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same quarter last year, the business posted $1.72 EPS. The company's revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.